Alliance Global initiated coverage of Iridex with a Buy rating and $3 price target. The ophthalmic medical technology company's key growth drivers include the Cyclo G6 laser system for the treatment of glaucoma and the Pattern Scanning Laser System for medical-retina indications, notes the analyst, who expects strong revenue growth for both the G6 laser system and the PASCAL.
